According to The Asahi Shimbun, transplanting corneal cells made from human induced pluripotent stem (iPS) cells into patients with a vision-impairing disease didn’t cause any serious side effects, researchers announced.
Some of the patients’ eyesight even improved as a result of the clinical trial, the team at Osaka University said.
“This could be a revolutionary treatment that could overcome the challenges that existing treatment has faced, such as a shortage of cornea donors or transplant rejection,” said Koji Nishida, a member of the team and professor of ophthalmology at the university, at a news conference.
Subscribe to our English Newsletter
© Japan Australia Business Creators Pty Ltd | All Rights Reserved. Website designed and developed by Japan Australia Business Creators Pty Ltd.